These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 35003069)
21. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma. Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393 [TBL] [Abstract][Full Text] [Related]
22. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients. Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792 [TBL] [Abstract][Full Text] [Related]
23. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443 [TBL] [Abstract][Full Text] [Related]
24. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers? Splendiani E; Besharat ZM; Covre A; Maio M; Di Giacomo AM; Ferretti E Pharmacol Ther; 2024 Apr; 256():108613. PubMed ID: 38367867 [TBL] [Abstract][Full Text] [Related]
25. Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma. Zhu Z; Li G; Li Z; Wu Y; Yang Y; Wang M; Zhang H; Qu H; Song Z; He Y Front Immunol; 2022; 13():914612. PubMed ID: 36072600 [TBL] [Abstract][Full Text] [Related]
26. A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma. Guo W; Zhu L; Zhu R; Chen Q; Wang Q; Chen JQ Elife; 2019 Jun; 8():. PubMed ID: 31169496 [TBL] [Abstract][Full Text] [Related]
27. uPAR Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390 [TBL] [Abstract][Full Text] [Related]
28. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma. Liu J; Lu J; Li W Front Immunol; 2021; 12():738068. PubMed ID: 34630418 [TBL] [Abstract][Full Text] [Related]
29. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. Dravillas CE; Coleman SS; Hoyd R; Caryotakis G; Denko L; Chan CHF; Churchman ML; Denko N; Dodd RD; Eljilany I; Hardikar S; Husain M; Ikeguchi AP; Jin N; Ma Q; McCarter MD; Osman AEG; Robinson LA; Singer EA; Tinoco G; Ulrich CM; Zakharia Y; Spakowicz D; Tarhini AA; Tan AC; Cancer Res Commun; 2024 Aug; 4(8):1978-1990. PubMed ID: 39015091 [TBL] [Abstract][Full Text] [Related]
30. Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients. Dufau C; Genais M; Mucher E; Jung B; Garcia V; Montfort A; Tosolini M; Clarke CJ; Medin JA; Levade T; Delord JP; Meyer N; Pancaldi V; Andrieu-Abadie N; Ségui B Front Immunol; 2024; 15():1421432. PubMed ID: 39136013 [TBL] [Abstract][Full Text] [Related]
31. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401 [TBL] [Abstract][Full Text] [Related]
32. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma. Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029 [TBL] [Abstract][Full Text] [Related]
33. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC). Jiang W; Zhu D; Wang C; Zhu Y Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345 [TBL] [Abstract][Full Text] [Related]
34. Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy. Karlsson MJ; Costa Svedman F; Tebani A; Kotol D; Höiom V; Fagerberg L; Edfors F; Uhlén M; Egyhazi Brage S; Maddalo G Cancer Res; 2021 May; 81(9):2545-2555. PubMed ID: 33574091 [TBL] [Abstract][Full Text] [Related]
35. Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma. Liu D; Yang F; Zhang T; Mao R J Transl Med; 2023 Jan; 21(1):57. PubMed ID: 36717900 [TBL] [Abstract][Full Text] [Related]
36. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680 [TBL] [Abstract][Full Text] [Related]
37. A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma. Mei Y; Chen MM; Liang H; Ma L Commun Biol; 2021 Mar; 4(1):383. PubMed ID: 33753855 [TBL] [Abstract][Full Text] [Related]
38. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604 [TBL] [Abstract][Full Text] [Related]
39. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042 [TBL] [Abstract][Full Text] [Related]
40. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]